

Sun Pharma acquires US-based Pharmalucence

16 July 2014 | News | By BioSpectrum Bureau



Singapore: After hitting headlines for its \$3.2 billion acquisition of Ranbaxy for months, leading Indian drug maker Sun Pharma has announced its buyout of a US based sterile injectables maker.

Pharmalucence is a sterile injectable capacity in the US and Sun Pharma has announced that it will be acquired by one of its subsidiaries.

The official statement by the company further said that the Pharmalucence is a leading manufacturer of radiopharmaceuticals and has developed a few injectables indicated for cancer treatment.

It added that Pharmalucence is engaged in contract and private label formulation development and manufacturing services of non-cytotoxic human injectables in either liquid or lyophilized form.

The statement further pointed out that in mid-2007, Pharmalucence was created via the management buy-out of CIS-US. Further, in 2011 and 2012, Pharmalucence received FDA approval for two new indications for its Sulfur Colloid product. Sulfur Colloid is indicated to assist in the localisation of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma.